Mironid Attendind J.P. Morgan Healthcare Conference

Our CEO Neil Wilkie, CMO Catherine (Cass) Kelleher, MD and CSO Adele Rowley will be attending the J.P. Morgan Healthcare Conference in San Francisco from January 13-16!

2024 was a transformative year for Mironid, with the nomination of our development candidate for ADPKD (Autosomal Dominant Polycystic Kidney Disease), a major step in our mission to develop first-in-class LoAc® therapeutics for a condition affecting over 12 million people worldwide.

If you’re attending and would like to connect, please reach out to schedule a meeting.

Learn about what we’ve been up to here: https://lnkd.in/dFTzZ76U

The Latest

Mironid Raises Awareness for PKD with 1,000 km Team ChallengeApril 14, 2026

At Mironid, we’re proud to support causes that make a meaningful difference. Last month, our team took part in the Polycystic Kidney Disease (PKD) Charity UK‘s ‘Spring into March’ challenge, raising awareness and supporting the [...]

Q&A with David Henderson, Head of BiologyMarch 19, 2026

ADPKD is a devastating disease that affects more than 12 million people worldwide. Over the past decade, there has been important progress in our understanding of the disease, with meaningful steps forward for both patients and clinicians. However, significant challenges remain. Tolerability [...]

Allosteric modulation of long-form PDE4 enzymes, a novel disease modifying treatment for Autosomal Dominant Polycystic Kidney DiseaseFebruary 18, 2026

Our Chief Scientific Officer, Adele Rowley, will be in London on 18 February for this year’s Ace Drug Discovery Summit, where she will be giving a presentation titled “Allosteric modulation of long-form PDE4 enzymes, a [...]